Cite
HARVARD Citation
Joos, G. et al. (2015). A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease. Respiratory medicine. 109 (5), pp. 606-615. [Online].